Measuring hand grip strength in people with pancreatic cancer
Measures hand grip strength with a handheld device in adults with pancreatic cancer.
Plain-language title generated from the registry record
Registry title: Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life
Key facts
- Where
- Vancouver, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with pancreatic ductal adenocarcinoma (PDAC) who are planned for treatment. It measures hand grip strength during regular clinic visits.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- PDAC that can be removed by surgery (only after surgery, as adjuvant treatment), cannot be removed by surgery, or has spread. ECOG performance status 0-2. Life expectancy greater than 6 months, as judged by the investigator.
- Earlier treatment
- Planned for treatment, either as routine care or together with an investigational drug in another study.
Main reasons for not taking part
- CT scans done outside Vancouver, BC, Canada
- Unfit for a CT scan of the third lumbar vertebra (L3)
- Currently in a structured moderate intensity resistance training program
- Unable to hold a dynamometer with one hand
- Unable to comply with study assessments and follow-up
Read by machine on 9 November 2026.
Where in Canada
- BC CancerVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- British Columbia Cancer Agency
- Trial code
- NCT07255001
- Record updated
- 15 September 2026
- Original description
The goal of this clinical trial is to measure hand grip strength in adults with pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are:Read full original descriptionShow less
Monitoring Physical Function Changes for Patients Living With Pancreatic Ductal Adenocarcinoma: Potential for Better Understanding of Treatment Trajectory and Survival
The goal of this clinical trial is to measure hand grip strength in adults with pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are:
* Is it feasible to measure hand grip strength as part of a clinic visit? * Are changes in hand grip strength related to changes in body composition? * Is hand grip strength related to a person's well-being? * Is hand grip strength related to how a tumour responds to treatment?
Participants will squeeze a device with their hand to measure their hand grip strength and complete questionnaires about their well-being when they are seen in clinic for their regular medical care for PDAC.
Inclusion: Age 18 years or older; Histological and/or radiological diagnosis of resectable, non-resectable, or metastatic PDAC. For resectable PDAC, adjuvant setting only; ECOG performance status 0-2; Life expectancy greater than 6 months as judged by the investigator; Planned for treatment, either as part of routine care or in combination with an investigational agent within another study; Ability to hold a dynamometer with one hand.
Exclusion: Individuals with CT imaging performed outside of Vancouver, BC, Canada; Individuals who are unfit to undergo CT imaging of the third lumbar vertebra (L3); Individuals who are currently participating in a structured moderate intensity resistance training program; Individuals who are otherwise judged by the investigator to be unfit to proceed with this protocol; Unable to comply with study assessments and follow-up.